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Background: Neurological events associated with transcatheter aortic valve implantation are major contributors to
morbidity and mortality. Choosing an appropriate endpoint to determine neuroprotection device efficacy is a key
difficulty inhibiting the translation of the innovation from the laboratory to the bedside. Cost and sample size
limitations inhibit the feasibility of using the rate of clinical (such as stroke or other cerebral) events as the primary
efficacy endpoint. This paper focuses on consensus opinions from the 2013 Yale-University College London (UCL)
Device Innovation Summit.
Discussion: Neuroimaging, specifically diffusion-weighted magnetic resonance imaging (DW MRI), may serve as a
surrogate endpoint for clinical studies detecting cerebral events in which cost and sample-size limitations prohibit
the use of clinical outcomes. A major limitation of using imaging to prove efficacy in cardiac device studies is that
no standardized endpoint exists. Ongoing trials investigating cerebral protection devices for transcatheter aortic
valve implantation are utilizing and reporting various qualitative and quantitative DW MRI values; however, single
lesion volume, number of new lesions, and total lesion volume have been found to be the most reproducible and
prognostically important imaging measures.
Summary: DW MRI may be a useful surrogate endpoint for clinical studies detecting cerebral events to determine
the device’s success in neurological protection. Consensus from the 2013 Yale-UCL Device Innovation Summit
specifically recommends the reporting of mean single lesion volume, number of new lesions, and total volume, and
encourages European Union (EU)-US regulatory consensus in the guidance of implementing this endpoint.Background
Neurological events contribute to the morbidity and
mortality associated with transcatheter aortic valve implant-
ation (TAVI). Neuroimaging, specifically diffusion-weighted
magnetic resonance imaging (DW MRI), may be a use-
ful tool for assessing clinical outcomes of both unpro-
tected TAVI as well as in the evaluation of cerebral
protection devices.
The current state of neuroprotection for TAVI is of
great interest among inventors and clinicians involved in
cardiac device development and implementation, and was* Correspondence: Alexandra.Lansky@yale.edu
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2013thus a primary focus of the 2013 Yale-University College
London (UCL) Cardiac Device Innovation Summit. This
meeting provided a forum for engineers and clinicians to
openly discuss the complexities of cardiac embolic protec-
tion devices, and address the unmet needs of the regula-
tory approval process to enhance percutaneous valvular
device innovation and clinical implementation.
The 2013 Yale-UCL summit focused on second-
generation TAVI, neuroprotection device development and
evaluation as adjunct to TAVI, percutaneous mitral valve
devices and left ventricular support devices, and novel per-
cutaneous coronary devices including biodegradable stent
technologies and targeted biologics. An expert faculty of
Europe-based and US-based regulators, industry partners,
funders, engineers and clinicians led various discussionstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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within the Yale and UCL campuses and open to all, with
no registration fees. The meeting was sponsored by Yale
University and UCL.
Choosing an appropriate endpoint to determine device
efficacy is a key difficulty inhibiting the translation of
the innovation from the laboratory to the bedside. The
Yale-UCL summit developed consensus recommendations
regarding the selection of study endpoints, specifically
for clinical trials investigating strategies for neuroprotection
in TAVI. Below, we will provide a brief discussion of TAVI-
related stroke and current strategies for neuroprotection,
and provide our conclusions recommending neuroimaging,
specifically DW MRI, as a cost-effective and potentially
even clinically meaningful endpoint to investigate efficacy
of cerebral protection devices for use in cardiac procedures.
TAVI-related stroke
There are several accepted therapies to treat severe aortic
stenosis but each is associated with significant risks. The
‘Placement of AoRTic TraNscathetER’ PARTNER trial and
other smaller studies have demonstrated the superiority of
TAVI to standard medical therapy for inoperable patients
with aortic stenosis and its non-inferiority to surgical valve
replacement for high risk patients, with such findings evi-
dent up to 2 years post procedure [1,2]. Further implemen-
tation of TAVI is limited by the risk of stroke, a devastating
contributor to morbidity and mortality in the typically older
and relatively frailer patient population undergoing such
endovascular procedures.
Indeed, the PARTNER trial demonstrated a two to three
times higher risk of stroke with TAVI compared with
standard medical therapy or surgery [1], and the rate of
TAVI-related stroke is estimated to be between 0% to 11%
[3-5], depending on patient and procedural characteristics.
The US Food and Drug Administration (FDA) cited the
rate of neurological adverse events as a significant concern
in approving the Edwards SAPIEN device [6]. Importantly,
advances in device technology have led to lower contem-
porary estimates of periprocedural stroke. In a recent meta-
analysis of >10,000 patients, Eggebrecht et al. determined
the incidence of stroke within the first 24 h of TAVI to be
1.5% ± 1.4%; other studies have found similar results [7,8].
Further, when compared to high-risk surgical cohorts, the
rates of complications in TAVI may even be similar to those
of surgical valve replacement [9,10]. Improved operator
experience and smaller insertion profiles may also de-
crease the incidence of stroke below that reported in the
PARTNER trial [11,12].
The TAVI procedure involves the introduction of bulky
devices into atherosclerotic arteries and a calcified aortic
valve, and thus lends itself to cerebral embolization of
plaque debris. The majority of TAVI-related strokes are in
fact periprocedural and >50% occur within the first 24 hof the procedure [1,13]. The cause of periprocedural neuro-
logical events during TAVI is probably multifactorial but
the pattern of cerebral ischemia following the procedure
suggests mechanical embolization of atherosclerotic debris
[13,14]. It has been shown that the highest rates of cerebral
embolization occur during valve positioning and implant-
ation [15]. Key steps that pose major risk include balloon
valvuloplasty, passage of a large-bore catheter, retrograde
travel through the aortic arch, and crushing of the native
valve leaflets [7]. Hypoperfusion due to rapid ventricular
pacing during balloon valvuloplasty or valve implantation
is also a possible contributor.
The importance of new lesions found on DWMRI, many
of which are clinically silent, remains unclear; however,
studies utilizing DW MRI have found new lesions in
58% to 91% of patients undergoing TAVI [15,16]. There
is increasing evidence from studies not involving TAVI
that the cumulative burden of ischemic brain injury may
cause neuropsychological deficits, aggravate vascular de-
mentia, and contribute to cognitive decline [17]. Notably,
these studies have shown that the 5-year survival is
considerably decreased for patients with vascular dementia
compared with age-matched controls (39% versus 75%)
[18]. However, though bright lesions on DW MRI are
commonly associated with ischemic lesions, they can
also be caused by migraines, seizures, or hypoglycemia,
and these events may contribute to the positive DW
MRI results seen in many patients undergoing TAVI.
The incidence of stroke within 30 days of the TAVI
procedure is estimated to be between 1.7% to 6.7%, and
there continues to be an increased risk of stroke in the
years following the procedure [1,19-21]. Post-procedural
neurologic events are likely caused by patient comorbidi-
ties such as atrial fibrillation, hypertension and possibly
atherosclerotic plaque or thrombus formation at the valve
level. Post-procedural DW MRI would have no advantage
in detecting or predicting such neurologic events.
Further, Kahlert et al. found that 80% of newly detected
lesions on DW MRI demonstrated reversal during the
3-month follow-up period; however, apparent lesion rever-
sal does not necessarily mean normalization of brain tissue
[15]. In fact, animal studies have shown that even after re-
versal, neurons exhibit structural damage with histological
staining suggesting that other non-neuronal cells may com-
pensate for the alterations in fluid balance [22].
Adjunctive pharmacology and neuroprotection devices
for TAVI
Given the increased risk of stroke associated with TAVI,
both adjunctive pharmacotherapy to prevent thrombosis
and neuroprotective devices may be indicated. The lit-
erature is scarce regarding the appropriate antithrom-
botic regimen for TAVI, and the few studies that have
been conducted have focused both on antiplatelet therapy
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(including bivalirudin and heparin). The only published
clinical trial to date randomized 79 patients undergoing
TAVI to receive a 300-mg loading dose of clopidogrel on
the date of procedure plus post-procedural maintenance
therapy consisting of 3 months of 75 mg of clopidogrel
daily plus aspirin 100 mg lifetime or aspirin 100 mg
alone. The results demonstrated no clinical benefit from
the addition of 3 months of clopidogrel maintenance ther-
apy [23]. This finding is important for patients with chronic
atrial fibrillation treated with daily warfarin and aspirin,
who demonstrate a significantly increased bleeding risk with
the addition of clopidogrel for catheterization procedures
[24]. Based on the findings of the aforementioned clinical
trial, aspirin therapy alone following TAVI is effective and
may improve the safety of patients with atrial fibrillation
undergoing the procedure. The ‘Effect of BivaliRudin
on Aortic Valve Intervention Outcomes’ (BRAVO) 2/3 study
will assess the safety and efficacy of using bivalirudin instead
of unfractionated heparin in TAVI with the hypothesis
that bivalirudin reduces bleeding rates and improves
clinical outcomes relative to heparin [25].
In addition to antithrombotic therapy, patients undergo-
ing TAVI may also benefit from the use of cerebral protec-
tion devices. The temporal pattern and location of cerebral
infarcts and silent ischemic lesions following TAVI indicate
periprocedural mechanical embolization as the most likely
pathophysiologic mechanism of periprocedural stroke.
We thus believe that there is a role for cerebral protection
devices in preventing stroke associated with TAVI. The
ideal protection device is safe, effective, easy to use, can
accommodate various anatomies, demonstrates minimal
interference with the TAVI procedure, and importantly,
covers all three major cerebral inflow aortic arch vessels.
Notably, using protection devices may make the TAVI
procedure more cumbersome, complicated, and time
consuming, and may thus drive up costs. Results from
the ‘Action in Diabetes and Vascular disease: PreterAx
and DiamicroN Controlled Evaluation’ (ADVANCE)
study link procedural time with the incidence of stroke,
suggesting that a fast and simple procedure may be one
of the most important factors for stroke prevention
(Johan Bosmans, University Hospital of Antwerp, Antwerp,
Belgium, personal communication). In addition, lower
contemporary stroke rates associated with TAVI raise the
question of whether cerebral protection devices and/or
adjunctive pharmacotherapy should be recommended for
all patients undergoing the procedure. Future randomized
controlled trials are needed to determine which patient
groups would benefit from these preventative measures.
If the increased stroke risk associated with TAVI remains
an issue in the future, the implementation of embolic
protection devices may be valuable in reducing both
clinically evident and occult strokes; however, if furtherstudies suggest that these risks have already been reduced,
additional devices may not be warranted.
Current embolic protection devices under clinical
investigation include the Edwards Embrella Embolic
Deflector (Edwards Lifesciences, Irvine, CA, USA), the
Keystone Heart TriGard™ Embolic Deflection Device
(Caesarea Business Park, Caesarea, Israel), and the Claret
CE Pro™ (Claret Medical, Santa Rosa, CA, USA) (Table 1).
While the Embrella and Claret CE Pro are only designed
to protect the brachiocephalic and left common ca-
rotid arteries, the Keystone Heart device is designed to
deflect debris away from all aortic arch cerebral inflow
vessels (brachiocephalic, left common carotid, and left
subclavian arteries) [26-28].
The only published human study of the Embrella device
reports the results of its implantation in three patients
undergoing TAVI and one patient undergoing BAV alone.
Though no patient developed new neurological symptoms
or stroke, a new 5-mm acute cortical infarct was found on
predischarge cerebral MRI in the patient who had under-
gone BAV but remained asymptomatic [26]. Unpublished
data of 38 endovascular cases with Embrella implantation
from 4 sites in Germany and Canada reported the occur-
rence of 2 device-related adverse events (1 CVA attributed
to malposition of the device, which resolved at discharge;
and 1 episode of blurred vision, cause undetermined) and
a 2.6% major adverse event rate. Comparison of DW MRI
with unprotected historical controls demonstrated similar
average numbers of lesions per subject (6.0 versus 4.69
[29] and 3.2 [16]) but a significant reduction in the average
volume of lesions in protected subjects versus unprotected
historical controls (5.9 cubic centimeters versus 0.394
cubic centimeters [29]) (John G Webb, St. Paul’s Hospital,
Vancouver, BC, Canada; personal communication).
Implantation of the Keystone Heart TriGard device in
15 patients resulted in no procedural complications and
1 patient suffering a transient ischemic attack 2 days
after the procedure [28]. DW MRI showed 3.2 new cerebral
lesions per patient in the study compared with 7.2 lesions
per patient in a historical unprotected control group;
however, lesion volumes were not reported [28]. In addition,
a study involving 40 patients and the Claret CE Pro also
revealed no periprocedural incidence of stroke with the
device; however, neither DW MRI nor transcranial Doppler
were performed. Results from the ongoing DEFLECT I trial
will provide DW MRI data in patients undergoing TAVI
with the TriGard device in place.
Results of the first in-human studies of neuroprotection
devices show promise in reducing the occurrence of
neurologic events and thus improving outcomes in TAVI.
DW MRI has been used to indicate periprocedural cere-
bral ischemia after unprotected TAVI in numerous studies
[15,29,30]. There are two published studies evaluating the
Embrella and TriGard cerebral protection devices, which
Table 1 Characteristics of current cerebral protection devices for transcatheter aortic valve implantation
Feature Edwards Embrella Embolic Deflector [26] Keystone Heart TriGard Embolic Deflection Device [28] Claret CE Pro [27]
Access Radial Femoral Radial
Position Aorta Aorta Brachiocephalic and LCC
Coverage area Brachiocephalic and LCC Brachiocephalic, LCC and LSC Brachiocephalic and LCC
Mechanism Deflection Deflection Capture
Size 6 F 9 F 6 F
Pore Size 100 microns Approximately 200 microns 140 microns
LCC left common carotid artery, LSC left subclavian artery.
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[26,28]; however, ongoing trials are studying mean or total
volume of new lesions, as discussed in the following
section. The use of various DW MRI endpoints to measure
device efficacy implores us to consider if an imaging end-
point is appropriate and if so, then how to define it. The
Yale-UCL summit evaluated these important questions and
our conclusions are reported below.
Discussion
Neuroimaging as an endpoint measure
Neuroimaging modalities, specifically transcranial Doppler
ultrasound (TCD) and DW MRI are useful for detecting
acute ischemic stroke and have provided additional infor-
mation about microembolization in TAVI. TCD uses low
frequency pulsed sound to allow visualization of the circle
of Willis vessels and can identify high-intensity transient
signals (HITS) and microembolic signals (MES). Studies
have found the detection of HITS in all patients undergoing
TAVI and the majority of MES occurring during balloon
valvuloplasty and valve delivery [31]. Unfortunately TCD is
highly operator dependent and requires considerable skill
and experience to attain accurate, reproducible results [32].
DW MRI is used to detect changes in the self-diffusion of
water molecules associated with ischemic injury. Given its
high sensitivity for detecting brain ischemia and widespread
availability, DW MRI is a suitable method for monitoring
neurovascular events during interventional procedures [33].
Choosing an appropriate endpoint for a clinical trial
can be complex. In fact, between 10% to 15% of medical
devices that enter the EU regulatory pathway lack relevant
endpoints, which is considered grounds for objection.
The penetration rate of devices in general, and in TAVI
specifically, is significantly delayed in the US compared
to Europe mostly due to FDA requirements for reasonable
assurance of safety and effectiveness of a device prior
to its approval [28].
For clinical trials investigating neuroprotection devices
for use in cardiac procedures, the investigators must
prove that the device is able to reduce the occurrence
and/or severity of cerebral events. Ideally this would be
accomplished by reporting an actual reduction in the rate
of stroke, transient ischemic attack, and other neurologicevents according to Valve Academic Research Consortium-
2 definitions [34]. Because the occurrence of TAVI-related
stroke is relatively low (<10%), a large sample size would be
needed to detect a difference in clinical event rate with
versus without a protection device. In addition to sample
size requirements, the rising cost of clinical trials limits
the feasibility of using relatively uncommon clinical events
as trial efficacy endpoints. Further, silent ischemia accounts
for the majority of lesions detected on neuroimaging fol-
lowing TAVI procedures. Using a clinical event endpoint to
measure device success would miss the occurrence of these
silent lesions, which are associated with cognitive decline
and mortality [17,18].
Neuroimaging, specifically DW MRI, may serve as a
surrogate endpoint for clinical studies detecting cerebral
events in which cost and sample size limitations prohibit
the use of clinical outcomes (Table 2). DW MRI, which has
sensitivity and specificity up to 92% and 97%, respectively,
combines features of conventional spin echo and gradient
echo techniques to image the freedom of the diffusion of
water molecules to identify restriction in diffusion, suggest-
ive of cerebral ischemia [35]. In cytotoxic edema due to
hypoxia, the redistribution of water from the extracellular
to the intracellular space is visible within 0 to 5 days of the
event (Figure 1). On DW MRI, normal tissue appears gray
due to the Brownian motion and diffusion of water mole-
cules, whereas restricted diffusion in the case of ischemia
prevents the normal loss of MRI signal and thus appears
white. A bright signal on DW MRI and a dark signal on
the corresponding apparent diffusion coefficient map is
characteristic of acute brain injury within 5 days.
One important issue to consider is that evidence for
long-term consequences of lesions detected by DW MRI
is lacking. Indeed, recent studies have implied that DW
MRI lesions after TAVI are not related to self-sufficiency
or mortality 1-year post procedure and that there may
even be less cognitive decline post TAVI compared with
surgery, despite a higher incidence of embolic lesions
[37,38]. These studies are limited by small sample sizes
but they suggest that there may limitations in utilizing
DW MRI to evaluate TAVI outcomes.
Another major limitation of using DW MRI in clinical
trials is that no clear definition of the endpoint exists.
Table 2 Clinical trial endpoints that may be used to demonstrate cardiac device efficacy in neuroprotection
Endpoint measure Advantages Disadvantages
Incidence of clinical outcomes (such as stroke,
transient ischemic attack)
Clear indicator of neurologic events Low incidence rate demands large sample size to observe effect
Can be reported in a standardized
fashion using the NIH stroke scale
and Modified Rankin scale.
Cost limitations may prohibit large sample size
May miss silent/subtle clinical events
Neuroimaging (such as diffusion-weighted
magnetic resonance imaging, transcranial
Doppler ultrasound)
Easy and reproducible No standardized definition of endpoint
Widely available Variation in reporting makes cross-study comparisons difficult
May be contraindicated in some patients
(for example, those with pacemakers)
Radiographic interpretation may be subjective
Biomarkers (such as S100β, apolipoprotein A1,
neuron-specific enolase)
Easy Validity not established
Reproducible Normal range for certain patient populations unknown
Objective Timing is critical
Less biased Expensive
Subject to laboratory errors
Figure 1 Diffusion-weighted magnetic resonance imaging (DW MRI) following transfemoral transcatheter aortic valve implantation in
an 86-year-old patient. Multiple acute ischemic lesions in the right cerebellum ((A), white arrow), white occipital territory ((B), white arrow), left
frontal and right parietal territories ((C), black arrows), and left and right frontal superior territories ((D), white arrows). Adapted with permission
from Rodes-Cabau et al. J Am Coll Cardiol 2011, 57:18–28 [36].
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vascular territory involved and quantitative measurements
include total lesion volume, average lesion volume, and
maximum lesion volume. All are key neuroimaging
endpoint parameters to follow the efficacy of neuroprotec-
tion, however, the endpoint must be standardized to allow
for cross-study comparison.
Ongoing clinical trials investigating cerebral protection
devices for TAVI are utilizing various DW MRI measures
to determine device efficacy. The ongoing Prospective
Randomized Outcome Study in Patients Undergoing TAVI
to Examine Cerebral Ischemia and Bleeding Complications
(PROTAVI) trial, which is randomizing patients eligible
for TAVI to undergo the procedure with or without the
Embrella deflection device, will analyze the rate of new
DW MRI brain lesions at 7 days post procedure. Likewise,
the DEFLECT I trial is a single arm study enrolling up
to 60 patients in the EU, Canada, and Brazil to undergo
TAVI with the Keystone Heart TriGard in place using
the presence of new DW MRI lesions post procedure
compared with a historical control group as a measure
of device success.
Although DW MRI lesion presence and rate of occur-
rence are being used as endpoints, total lesion volume is
the most reproducible measurement when performed in
an experienced core laboratory, and along with geographic
location, provides the best measure of overall burden
of ischemic injury, and may therefore be a more appro-
priate endpoint measure. Though it fails to identify the
functional region of the brain involved, studies have
identified DW MRI lesion volume as an independent
predictor of clinical outcome after acute stroke [39,40].
Specifically, mean lesion volume has been correlated
with mental changes and vascular dementia following
endovascular procedures [41]. In contrast, the presence
and number of DW MRI lesions are only likely to be clin-
ically relevant if the individual lesion is large or in an area
of functional significance [42]. Therefore, the Yale-UCL
summit concluded that DW MRI lesion volume should be
measured by independent core laboratory assessment with
validated and reproducible methodology and should be in-
cluded and reported in all clinical studies using DW MRI
to investigate neuroprotection devices for use in TAVI.
We recommend that single lesion volume, number of new
ischemic lesions, and total lesion volume be measured.
Lastly, in 2011, the FDA issued draft guidance for clinical
trial imaging endpoints for studies intending to confirm
drug efficacy, recognizing that the use of imaging may
assist in the assessment of safety and efficacy as well as
patient eligibility. US regulatory requirements have been
an impediment to early clinical testing of new devices,
which US investigators have mostly outsourced overseas.
During the Yale-UCL summit, the FDA expressed its goals
to encourage medical device innovation, enhance regulatoryscience, and facilitate early feasibility clinical studies in
the US. Consensus from the Yale-UCL summit called
for validation of imaging endpoints in neuroprotection
trials involving medical devices and encouraged European
regulatory bodies and the FDA to work with the clinical
and device industry to support this position.
Summary
In summary, stroke is a major contributor to morbidity
and mortality in TAVI and the development of effective
cerebral protection devices may optimize clinical outcomes.
Though periprocedural outcomes may already be better
than previously thought, it is still necessary to confirm
the rates of neurological events in a consistent and reli-
able manner. Sample size requirements and rising costs
of clinical trials are prohibitive to the use of clinical event
rates as device efficacy endpoints. The 2013 Yale-UCL
Summit developed consensus opinions regarding this
topic. DW MRI may be a sensitive and specific surrogate
endpoint for clinical studies detecting cerebral events to
determine the device’s success in neurological protection;
however, further research is needed. Finally, for clinical
trial investigators using DW MRI as an endpoint to detect
cerebral events, we recommend the reporting of mean
single lesion volume, number of new lesions, and total
volume, as we have concluded that these values are the
most reproducible and potentially even prognostically
meaningful DW MRI measures.
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